Abstract
Objective:The goal of this study was to investigate whether gestational trophoblastic disease (GTD) and healthy pregnancy differ with respect to complete blood count parameters and these parameters can be used both to explain the pathophysiologic mechanisms and differentiate the two conditions from each other.Methods:The data obtained from 37 women with GTD and 61 healthy pregnancies (control group) regarding platelet (PLT), mean PLT volume (MPV) and PLT distribution width (PDW), and white blood cell (WBC) levels were evaluated. Patients with GTD were further subdivided into two groups composed of 20 partial mole (PM) and 17 complete mole (CM) cases.Results:PDW and WBC were lower in the GTD than the control. There were no differences for PLT and MPV. WBC was lower in PM and both WBC and PDW were lower in CM compared with control. ROC curve analysis revealed an area under curve (AUC) 75.5% for WBC and AUC 69.3% for PDW. A cut-off value was determined 8.19 for WBC with 81.0% sensitivity and 54.1% specificity. While, 15.85 were accepted for PDW, with 87.9% sensitivity and 44.4% specificity.Conclusion:Lower WBC in GTD may suggest that molar pregnancy requires a lower inflammatory reaction facilitating trophoblastic invasion. Lower PDW as an indicator of platelet activation in CM may suggest that CM requires less PLT activation than healthy pregnancy that needs stronger trophoblast invasion for normal placental development. Decreased PDW levels especially < 15.85 and WBC levels < 8.19 may alert clinicians for risk of GTD.
Highlights
Gestational trophoblastic disease (GTD) is a tumor characterized by proliferation of trophoblasts originating from the placenta
PLT, mean platelet volume (MPV), PLT distribution width (PDW), white blood cell (WBC) levels of GTD (PM and complete mole (CM)) and control groups were shown on Table-II
PDW level was significantly lower in GTD than the controls, and this difference was largely driven by the patients with CM
Summary
Gestational trophoblastic disease (GTD) is a tumor characterized by proliferation of trophoblasts originating from the placenta. It has a wide clinical spectrum consisting of partial (PM) and complete hydatidiform mole (CM), invasive mole, choriocarcinoma, and placental site trophoblastic tumor. Trophoblastic neoplasia (invasive mole or choriocarcinoma) occurs in 15-20% of CM and less than 5% of PM. Gestational trophoblastic neoplasia are potentially curable even in the presence of widespread metastatic disease. More than 90% of patients with partial mole have symptoms of incomplete or missed abortion, and the diagnosis is usually made after histological examination of curettage specimens.[3] Beta human chorionic gonadotropin (beta - hCG) as a serum biochemical parameter is most commonly used in diagnosis and monitoring of GTD. Beta - hCG levels should be monitored as a surrogate marker for regression during disease and after treatment.[4]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
